Skip to main content
Erschienen in: Virchows Archiv 5/2015

01.05.2015 | Original Article

Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor

verfasst von: Hongmei Li, Ondrej Hes, Gregory T. MacLennan, Daniel C. Eastwood, Kenneth A. Iczkowski

Erschienen in: Virchows Archiv | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Metastases of clear cell renal cell carcinoma to the adrenal can mimic primary adrenal cortical neoplasms or normal adrenal, especially in biopsy material. We compared 34 cases of clear cell renal cell carcinoma metastasis to the adrenal with 49 primary adrenal lesions (16 carcinoma, 22 adenoma, 9 oncocytic tumor, and 2 hyperplasia). Normal adrenal was available in 59 cases. Each entity was represented on tissue microarrays by duplicate-triplicate evaluable spots taken from spatially separate areas. Two pathologists evaluated all reactivity from 0 to 3+. A panel of 12 immunohistochemical stains was performed, including the first diagnostic uses of steroid receptor coactivator (SRC1) and equilibrative nucleoside transporter 1 (ENT1). The most sensitive and specific renal cell carcinoma markers were membranous reactivity for carbonic anhydrase IX (CAIX) and RCC marker and nuclear reactivity for PAX8. For adrenal cortical carcinomas, best markers were synaptophysin, SRC1, and MelanA; and for adrenal oncocytic tumor, synaptophysin and ENT1. Optimal markers for adrenal cortical adenoma and normal adrenal were ENT1 (more specific) and either MelanA or SRC1 (more sensitive). Calretinin, cytokeratin 34βE12 and CAM5.2, inhibin, and steroidogenic factor 1 (SF1) proved less valuable to the panel. Nonspecific cytoplasmic biotin reactivity was frequent for CAIX and PAX8. Tumors with high-grade cytology should be worked up with 2 of the 3 stains: CAIX, PAX8, or RCC marker; and either SRC1 or MelanA. Adrenal adenoma, or normal adrenal, versus low-grade renal cell carcinoma are distinguished by a panel of: CAIX, PAX8, or RCC Marker; ENT1 and either SRC1 or MelanA.
Literatur
1.
Zurück zum Zitat Weissferdt A, Phan A, Suster S, Moran CA (2014) Adrenocortical carcinoma: a comprehensive immunohistochemical study of 40 cases. Appl Immunohistochem Mol Morphol 22:24–30CrossRefPubMed Weissferdt A, Phan A, Suster S, Moran CA (2014) Adrenocortical carcinoma: a comprehensive immunohistochemical study of 40 cases. Appl Immunohistochem Mol Morphol 22:24–30CrossRefPubMed
2.
Zurück zum Zitat Sangoi AR, McKenney JK (2010) A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am J Surg Pathol 34:423–432CrossRefPubMed Sangoi AR, McKenney JK (2010) A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am J Surg Pathol 34:423–432CrossRefPubMed
3.
Zurück zum Zitat Zhang H, Bu H, Chen H, Wei B, Liu W, Guo J, Li F, Liao D, Tang Y, Zhang Z (2008) Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors. Appl Immunohistochem Mol Morphol 16:32–39PubMed Zhang H, Bu H, Chen H, Wei B, Liu W, Guo J, Li F, Liao D, Tang Y, Zhang Z (2008) Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors. Appl Immunohistochem Mol Morphol 16:32–39PubMed
4.
Zurück zum Zitat McCluggage WG, Burton J, Maxwell P, Sloan JM (1998) Immunohistochemical staining of normal, hyperplastic, and neoplastic adrenal cortex with a monoclonal antibody against alpha inhibin. J Clin Pathol 51:114–116CrossRefPubMedCentralPubMed McCluggage WG, Burton J, Maxwell P, Sloan JM (1998) Immunohistochemical staining of normal, hyperplastic, and neoplastic adrenal cortex with a monoclonal antibody against alpha inhibin. J Clin Pathol 51:114–116CrossRefPubMedCentralPubMed
5.
Zurück zum Zitat Loy TS, Phillips RW, Linder CL (2002) A103 immunostaining in the diagnosis of adrenal cortical tumors: an immunohistochemical study of 316 cases. Arch Pathol Lab Med 126:170–172PubMed Loy TS, Phillips RW, Linder CL (2002) A103 immunostaining in the diagnosis of adrenal cortical tumors: an immunohistochemical study of 316 cases. Arch Pathol Lab Med 126:170–172PubMed
6.
Zurück zum Zitat Enriquez ML, Lal P, Ziober A, Wang L, Tomaszewski JE, Bing Z (2012) The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms. Appl Immunohistochem Mol Morphol 20:141–145CrossRefPubMed Enriquez ML, Lal P, Ziober A, Wang L, Tomaszewski JE, Bing Z (2012) The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms. Appl Immunohistochem Mol Morphol 20:141–145CrossRefPubMed
7.
Zurück zum Zitat Pan CC, Chen PC, Tsay SH, Ho DM (2005) Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol 13:347–352CrossRefPubMed Pan CC, Chen PC, Tsay SH, Ho DM (2005) Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol 13:347–352CrossRefPubMed
8.
Zurück zum Zitat Sangoi AR, Fujiwara M, West RB, Montgomery KD, Bonventre JV, Higgins JP, Rouse RV, Gokden N, McKenney JK (2011) Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol 35:678–686CrossRefPubMedCentralPubMed Sangoi AR, Fujiwara M, West RB, Montgomery KD, Bonventre JV, Higgins JP, Rouse RV, Gokden N, McKenney JK (2011) Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol 35:678–686CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Erickson LA, Jin L, Sebo TJ, Lohse C, Pankratz VS, Kendrick ML, van Heerden JA, Thompson GB, Grant CS, Lloyd RV (2001) Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. Endocr Pathol 12:429–435CrossRefPubMed Erickson LA, Jin L, Sebo TJ, Lohse C, Pankratz VS, Kendrick ML, van Heerden JA, Thompson GB, Grant CS, Lloyd RV (2001) Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. Endocr Pathol 12:429–435CrossRefPubMed
10.
Zurück zum Zitat Weissferdt A, Phan A, Suster S, Moran CA (2013) Myxoid adrenocortical carcinoma: a clinicopathologic and immunohistochemical study of 7 cases, including 1 case with lipomatous metaplasia. Am J Clin Pathol 139:780–786CrossRefPubMed Weissferdt A, Phan A, Suster S, Moran CA (2013) Myxoid adrenocortical carcinoma: a clinicopathologic and immunohistochemical study of 7 cases, including 1 case with lipomatous metaplasia. Am J Clin Pathol 139:780–786CrossRefPubMed
11.
Zurück zum Zitat Hu Y, Hartmann A, Stoehr C, Zhang S, Wang M, Tacha D, Montironi R, Lopez-Beltran A, Cheng L (2012) PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. J Clin Pathol 65:254–256CrossRefPubMed Hu Y, Hartmann A, Stoehr C, Zhang S, Wang M, Tacha D, Montironi R, Lopez-Beltran A, Cheng L (2012) PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. J Clin Pathol 65:254–256CrossRefPubMed
12.
Zurück zum Zitat Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Ahmadie HA, Fine SW et al (2011) Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol 24:1207–1220CrossRefPubMed Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Ahmadie HA, Fine SW et al (2011) Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol 24:1207–1220CrossRefPubMed
13.
Zurück zum Zitat Lin BT, Bonsib SM, Mierau GW, Weiss LM, Medeiros LJ (1998) Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. Am J Surg Pathol 22:603–614CrossRefPubMed Lin BT, Bonsib SM, Mierau GW, Weiss LM, Medeiros LJ (1998) Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. Am J Surg Pathol 22:603–614CrossRefPubMed
Metadaten
Titel
Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor
verfasst von
Hongmei Li
Ondrej Hes
Gregory T. MacLennan
Daniel C. Eastwood
Kenneth A. Iczkowski
Publikationsdatum
01.05.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 5/2015
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-015-1732-9

Weitere Artikel der Ausgabe 5/2015

Virchows Archiv 5/2015 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …